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tion prescribed between July 2013 and June 2014. Results: Of 2,558 CHC treated 
patients, 142 patients (5.6%) were identified as having CKD . The mean age of CHC 
patients with CKD was 61 years compared to 57 years among those without CKD 
(p< .0001). Compared to CHC patients without CKD (n = 2,416), patients with CKD had 
significantly more comorbidities including diabetes (53% vs 23%, p< .0001), major 
depression (15% vs.6%, p= .0007), hypertension (85% vs. 51%, p< .0001) and heart 
failure (19% vs. 2%, p< .0001). CHC patients with CKD also had higher prevalence 
of kidney transplants (11% vs.1%, p< .0001) and more liver transplants (35% vs. 6%, 
p< .0001). For concomitant drug use, CHC patients with CKD had significantly more 
concomitant drugs (by drug class) during the 2-year baseline period compared to 
those without CKD (17 vs 11, p< .0001). Average annual out-of-pocket pharmacy 
expenses at baseline were significantly higher among CHC patients with CKD com-
pared to those without CKD ($1,079 vs. $606, p< .0001). ConClusions: In a US 
commercially insured population, treated CHC patients with CKD had significantly 
higher rates of comorbidities and drug utilization compared to those without CKD.
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objeCtives: To assess adherence in clinical practice of HIV patients switching to 
emtricitabina+tenofovir disoproxil+rilpivirin Methods: An observational retro-
spective cohort analysis, based on administrative databases from four Italian LHUs. 
The date of the first prescription of emtricitabina+tenofovir disoproxil+rilpivirin 
between January, 2010 and December, 2013 has been used as the index date. Patients 
were characterized back in previous 12 months to assess HIV treatments, and fol-
lowed up after index date for 12 months, date of death, or exiting the database 
(whatever came first). Non-adherence, as well as selective non-adherence, to antiret-
roviral medications were calculated using pharmacy refill compliance data in pre/
post index date period. Non-adherence measures were expressed in percentages of 
days spent either without all prescribed antiretrovirals (complete non-adherence) 
or without at least one of the prescribed regimen components (selective non-
adherence) on total days prescribed Results: During the observation period, 87 
patients switched to emtricitabina+tenofovir disoproxil+rilpivirin: 10 from Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 62 from efavirenz+emtricita
bina+tenofovir disoproxil (EFV/TDF/FTC) and 15 from Protease Inhibitors (PIs). Post-
switch non-adherence among the 87 patients switching to emtricitabina+tenofovir 
disoproxil+rilpivirin was around 4%, with small differences according to previous 
anti-retroviral therapies (4.7% in previously NNRTIs-treated, 4.2% in efavirenz+em
tricitabina+tenofovir disoproxil group and 3.2% in patients with previous PIs). For 
all of them, pre-switch non-adherence showed much higher values: from NNRTIs 
20.8% selective non-adherence, 30.5% to all drugs; from EFV/TDF/FTC 10.7%; from 
PIs 14.2% selective, 25.8% to all ConClusions: In this preliminary analysis, switch-
ing to emtricitabina+tenofovir disoproxil+rilpivirin increased treatment adherence 
with respect to previous therapies. This phenomenon was highly evident in patients 
coming from NNRTIs and PIs, who reported an absolute decrease in non-adherence 
rates of 46.6% and 36.8%, respectively
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objeCtives: The aim of this study is to determinate the minimum indicators to 
evaluate management and clinical results in institutions assisting patients living 
with HIV in Colombia, between different actors of the Health System. Methods: 
The Colombian Association of Infectology, health insurance companies, govern-
mental entities, international agencies and professionals leaders in attention of HIV 
patients were invited in order to have a consensus. Literature research in different 
databases like PubMed, Embase and Cochrane using Mesh terms was used. 3.023 
articles were found. After reading the titles 414 articles were selected, but finally 20 
articles were included. Experts reviewed the articles and raised indicators, then all 
system actors, selected the final indicators. Results: 17 indicators were selected 
and then classified in 4 groups. In the initial evaluation indicators included the 
proportion of patients with diagnosis of HIV who had attention with expert doc-
tors, patients with report of CD4, patients with viral load and patients with report 
of Lymphocytes. Monitoring indicators included the proportion of people with 
annual PPD, people with report of CD4 and viral load in the last 6 month, patients 
with annual syphilis screening and patients with cardiovascular risk assessment. 
Therapy indicators included the proportion of pregnant using anti-retroviral agents, 
patients with antitubercular agents. Furthermore, proportion of HIV people with 
undetectable viral load in the 48 weeks or more since the beginning of the treatment 
with antiretroviral agents, and others. Finally, the specific prevention indicators 
were related with people with latent tuberculosis treatment, prophylaxis for pneu-
monia by Pneumocystis Jirovecii and a proportion of people with complete vaccina-
tion schedule for Hepatitis B. ConClusions: Formulating indicators to institutions 
assisting patients living with HIV could decrease health inequalities in the attention 
of this population and will have a positive impact in HIV patients health results.
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ous stages. We perform sensitivity analysis in order to understand the attractiveness 
of various incentive schemes. Results: Once antibiotic development has success-
fully moved past the pre-clinical stages, incentives appear to not have all that much 
influence on investment decisions. At the pre-clinical stage, however, investment 
decisions are sensitive to incentives. Out of the incentives assessed, those rewarding 
success at the pre-clinical stage are the most effective at encouraging pre-clinical 
development. Incentives given further downstream are less attractive to develop-
ers due to the magnitude of upfront expenditure; the time value of money and 
associated development risks. ConClusions: A decision option approach to the 
valuation of antibiotics allows for a clear understanding of the value throughout the 
development cycle and allows us to assess the best structure for incentives aimed 
at encouraging antibiotic development.
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objeCtives: The aim of our examination was to evaluate knowledge of educated 
nurses on the prevention of infections due to inappropriate decontamination of 
nursing tools and patient environments and on nosocomialis infections and infec-
tion control. Methods: We carried out our cross-sectional, quantitative examina-
tion between 1.12.2014 and 28.02.2015 in 12 inpatient wards of a county hospital in 
Hungary. Our participants were educated nurses (N= 103), and for data collection we 
used two questionnaires: one with only closed-ended questions and one with only 
open-ended questions. We used Microsoft Office Excel 2002 software to carry out 
descriptive statistics, χ 2-test and two-sample t-test (p< 0.05). Results: On average, 
nurses scored higher in case of the questionnaire with closed-ended question that 
in case of the questionnaire with open-ended questions (p= 0.021). Average scores of 
nurses working at an intensive care ward was significantly higher than nurses work-
ing at other wards (p< 0.001). Nurses working in health care for longer time find the 
prevention of nosocomialis infections more important (p< 0.05). We found significant 
difference in case of the preparatory board, the PC keyboard, the patient’s bedside 
table, the telephone and the nurse-bell (p< 0.05), unlike in case of the door handle 
(p= 0.081). ConClusions: Knowledge of nurses on nosocomialis infections is not 
satisfactory at all fields. Nosocomialis infections occur the most often at intensive 
care wards, thus nurses working at that ward have the most extensive knowledge 
on the topic. Participants scored higher in case of the closed-ended questionnaire 
and chose the best answer more easily. Nurses do not consider the infectedness 
of the patient- or working environment highly important, although the play and 
important role in transferring nosocomialis infections.
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objeCtives: This study described patient characteristics and real world drug utili-
zation among patients diagnosed with CHC in the US. Methods: We conducted a 
retrospective database study using the Truven Health MarketScan® database. Patients 
were identified with ≥ 2 HCV medical claims (ICD-9: 070.54, 070.44, 070.70, 070.71) 
≥ 1 month apart (to define chronic illness), and had 3-year continuous enrollment 
in order to capture treatment experience. The CHC treated cohort was defined as 
those who had ≥ 1 HCV medication filled from 7/1/2013 to 30/6/2014. Results: 
Compared to untreated patients (n = 13,953), CHC treated patients (2,558) had a 
higher prevalence of liver transplants (7% vs 3%, p< .0001), cirrhosis (40% vs 20%, 
p< .0001), and comorbidities (Charlson Comorbidity index= 3.9 vs. 3.3, p< .0001). Of 
2,558 treated CHC patients, patients were treated by SOF/IFN/RBV (n= 580), SOF/RBV 
(n= 587), SOF/SMV (n= 511), INF/RBV (n= 342), BOC/IFN/RBV (n = 83), TEL/IFN/RBV 
(n = 162), and other regimens (n= 293). Across all the regimens, the mean age ranged 
from 53-59 years, and majority were male (60%-69%). Among patients receiving SOF/
IFN/RBV, SOF/RBV, SOF/SMV, INF/RBV, BOC/IFN/RBV or TEL/IFN/RBV therapy, cirrhosis 
was observed in 31%, 43%,55%,32%, 37%, and 28% respectively (p< 0.001). While the 
majority of patients treated with BOC/IFN/RBV (90%) or INF/RBV (69%) were HCV 
treatment experienced, only ~10% of patients with SOF-based regimen had prior 
HCV treatment (p< .0001). Patients treated with SOF/SMV had significantly more 
comorbidities compared to other regimens (p< 0.001); 13% of had prior liver trans-
plants compared to 7% of both SOF/RBV and INF/RBV patients and 2% of SOF/IFN/
RBV (p< .0001). ConClusions: In an insured population, treated CHC patients had 
higher rates of comorbidities and cirrhosis compared to untreated patients. While 
the majority of CHC patients with SOF-based regimen were treatment naïve, patients 
treated with SOF/SMV had higher comorbidities compared to other regimens.
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objeCtives: To compare patient characteristics and drug utilization among 
CHC patients with and without CKD in a US treated CHC population. Methods: 
De-identified, individual-level healthcare claims data from Truven Health 
MarketScan® database was analyzed. CHC was defined as those who had ≥ 2 medi-
cal claims of HCV (ICD9: 070.54, 070.44, 070.70, 070.71) ≥ 1 month apart. Three-year 
continuous enrollment was required in order to capture prior treatment experience. 
The CHC treated cohort was defined as those who had at least 1 HCV medica-
